Carisma Therapeutics (CARM) AI Stock Analysis

• Market Cap: $46.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: 32.45%
• EPS Growth: 39.31%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 41,788,097
• 10 Day Avg. Volume: 4,008,064
• 30 Day Avg. Volume: 1,942,278
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 0.21
• Enterprise Value/Gross Profit: 0.91
• Enterprise Value/Ebitda: -0.07
• 1Y Price Target: $1.00
• Price Target Upside: 66.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $0.50 ▼(-16.67%Downside)

The overall stock score is primarily influenced by the significant financial challenges Carisma Therapeutics is facing, including unstable financial statements and negative valuation metrics. While technical analysis shows some positive momentum, these factors are outweighed by the financial and valuation concerns. The lack of earnings call details and corporate events means the score is largely driven by core financial and market data.

Positive Factors

Cash Flow and Financial Stability

The company expects its current cash runway to last through the third quarter of 2025, providing a degree of financial stability.

Partnerships and Collaborations

Carisma's focus is now on partnered programs with Moderna, including a GPC3-targeted program and a liver-fibrosis program, showing potential future growth areas.

Negative Factors

Program Discontinuation and Restructuring

Carisma announced the discontinuation of their lead HER-2 monocyte program CT-0525 due to lack of strong enrollment and evolving clinical landscape.

Rating Downgrade

The rating for Carisma has been downgraded from Buy to Neutral due to a lack of near-term catalysts and a financing overhang.

Carisma Therapeutics Business Overview & Revenue Model

Company Description

Carisma Therapeutics (CARM) is a biotechnology company focused on the development of innovative cellular therapies aimed at treating cancer and other serious diseases. Utilizing its proprietary chimeric antigen receptor macrophage (CAR-M) technology, Carisma is pioneering a new class of immunotherapy treatments that harness the body's own immune system to target and eliminate cancer cells. The company's core product pipeline includes several promising candidates in various stages of clinical development, addressing unmet medical needs in oncology and beyond.

How the Company Makes Money

Carisma Therapeutics generates revenue primarily through the development and commercialization of its proprietary CAR-M technology-based therapies. The company's revenue streams include potential product sales upon successful approval and market entry of its therapeutic candidates. Additionally, Carisma may engage in strategic collaborations and partnerships with other pharmaceutical companies, allowing for co-development, licensing agreements, and milestone payments. These partnerships provide financial support and accelerate the development of its therapeutic pipeline. Furthermore, Carisma may receive research grants and funding from governmental or non-profit organizations that support innovative cancer treatment research, contributing to its overall earnings.

Carisma Therapeutics Financial Statement Overview

Summary

Carisma Therapeutics is facing significant financial challenges. The income statement shows volatile revenue and negative profitability metrics. The balance sheet highlights instability with negative stockholders' equity and a high debt-to-equity ratio. Cash flow concerns persist with consistently negative free cash flow, indicating difficulty in generating cash from operations.

Income Statement

Carisma Therapeutics has shown a volatile revenue pattern, with the latest TTM revenue slightly increasing. However, the company is struggling with profitability, evident from negative EBIT and net profit margins. The negative revenue growth in recent years indicates challenges in market expansion.

Balance Sheet

The balance sheet reflects significant financial instability with negative stockholders' equity and a high debt-to-equity ratio. The negative equity ratio highlights potential solvency issues, which could pose risks to long-term sustainability.

Cash Flow

Cash flow analysis reveals concerns, with consistently negative free cash flow indicating challenges in generating cash from operations. The operating cash flow to net income ratio is unfavorable, suggesting difficulties in converting revenue into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
19.96M	19.63M	14.92M	9.83M	26.54M	11.24M
	Gross Profit
19.04M	19.63M	-59.21M	3.74M	26.46M	11.24M
	EBIT
-52.00M	-62.18M	-88.73M	-56.16M	-40.79M	-28.38M
	EBITDA
-49.46M	-57.12M	-85.89M	-51.99M	-40.11M	-27.93M
	Net Income Common Stockholders
-50.77M	-60.48M	-86.88M	-61.23M	-40.77M	-28.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.74M	17.91M	77.61M	52.00M	28.55M	51.79M
	Total Assets
15.95M	30.46M	89.55M	72.15M	35.45M	58.46M
	Total Debt
2.33M	2.48M	3.12M	40.16M	2.63M	3.44M
	Net Debt
-5.42M	-15.43M	-74.48M	15.97M	-25.92M	-48.34M
	Total Liabilities
52.62M	58.37M	63.02M	101.28M	9.43M	8.31M
	Stockholders Equity
-36.66M	-27.91M	26.53M	-49.26M	11.63M	35.76M
Cash Flow		Free Cash Flow
-47.66M	-60.04M	-82.31M	-12.23M	-39.20M	-27.45M
	Operating Cash Flow
-47.56M	-59.92M	-81.18M	-7.57M	-37.33M	-27.01M
	Investing Cash Flow
418.00K	-123.00K	72.41M	-32.56M	-1.87M	-440.00K
	Financing Cash Flow
-1.63M	344.00K	62.18M	35.77M	15.96M	72.26M

Carisma Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CARM, the sentiment is Positive. The current price of 0.6 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.23, and above the 200-day MA of 0.59, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 61.43 is Neutral, neither overbought nor oversold. The STOCH value of 73.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CARM.

Carisma Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPRX	56 Neutral	$10.17M	4.67	-41.13%	―	―	―
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
DWTX	49 Neutral	$9.42M	―	-451.34%	―	―	-57.84%
CARM	48 Neutral	$46.38M	―	-362.79%	―	32.45%	39.31%
ACXP	39 Underperform	$8.30M	―	-285.79%	―	―	23.65%
TSBX	34 Underperform	$8.40M	―	-126.03%	―	-100.00%	-27.44%

Carisma Therapeutics Corporate Events

Carisma Therapeutics Secures Nasdaq Listing Approval

On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.